A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
Glioblastoma (GBM) is one of the most common primary and deadliest malignant brain tumor with chemoresistance and poor prognosis. There is a lack of effective chemotherapeutic drug for the treatment of GBM. In this work, we reported the preparation of a histone deacetylase (HDAC) inhibitor, DMC-HA,...
Enregistré dans:
Auteurs principaux: | Hao Wang, Lei Shi, Zhimin Wang |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/2a623b45d799404f8abce9b4458c3db7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
par: Tandon N, et autres
Publié: (2016) -
Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer
par: Bingyi Zhou, et autres
Publié: (2021) -
GM101 in Combination with Histone Deacetylase Inhibitor Enhances Anti-Tumor Effects in Desmoplastic Microenvironment
par: Han-Gyu Chang, et autres
Publié: (2021) -
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <italic toggle="yes">Ex Vivo</italic> Lipopolysaccharide-Induced Inflammatory Responses
par: Christel Rothe Brinkmann, et autres
Publié: (2018) -
Identification of the Histone Deacetylases Gene Family in Hemp Reveals Genes Regulating Cannabinoids Synthesis
par: Liu Yang, et autres
Publié: (2021)